Biopharmaceutical Trends In 2012: Regulatory And Market Strides Paper Over Existential Dilemmas

The biopharma industry enjoyed regulatory success in 2012 that was recognized by investors. The stench from the carcasses of industry’s genericized blockbusters has begun to fade, but R&D productivity for the most part remains poor, expensive late-stage failures abound, and industry is still searching for sustainable business models.

The relative buoyancy of biopharma in 2012 can perhaps be viewed most favorably through the lens of the continued success industry in general enjoyed at FDA and that biotechs in particular enjoyed on the stock market. But despite this good fortune, and despite investors’ willingness at times to see beyond companies’ patent cliffs and into emerging pipelines, many of industry’s largest companies continue to struggle as big development bets fail to pay off.

Importantly, the broader biopharma world continues to grapple with the same existential questions: where should new drugs come from; how should industry fund their discovery and development; what drugs are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.